The result was consistent with the findings in NSCLC patients with EGFR mutations (RR 0.12, 95% CI 0.04–0.34 and RR 1.07, 95% CI 0.64–1.78, separately). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.